

# BioMarin to Provide Updated Data for BMN 270 in Hemophilia A in Late Breaking Oral Presentation at the World Federation of Hemophilia (WFH) 2016 World Congress July 27th

## Conference call and web-cast to be held Wednesday, July 27th at 4:05pm ET

SAN RAFAEL, Calif., July 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that interim results of an open-label, Phase 1/2 study of BMN 270, an AAV5-FVIII Gene transfer in severe Hemophilia will be presented at the XXXII International Congress of the World Federation of Hemophilia. BMN 270 has received orphan drug designation from the European Commission and U.S. Food and Drug Administration. BioMarin management to hold conference call and webcast to discuss the data on Wednesday, July 27, at 4:05pm ET.

The data will be presented in the Late Breaking Gene Therapy session between 2:15pm-3:45pm ET in Room Hall A 4 by John Pasi, Professor of Haemostasis and Thrombosis, Barts and the London School of Medicine, Honorary Consultant Haematologist, The Royal London Hospital, a lead investigator on the study. The data presented at the WFH congress will be updated since the Company reported preliminary data April 20, 2016.

## Conference Call to be Held Wednesday, July 27<sup>th</sup> at 4:05pm ET

Interested parties may access a live webcast of the conference call via the investor section of the BioMarin website, [www.biomarin.com](http://www.biomarin.com). The Late Breaker slide presentation will be available to download in advance of the call. A replay of the will be archived on the site for one week following the call.

U.S. / Canada Dial-in Number: (866) 502-9859

International Dial-in Number: (574) 990-1362

Conference ID: 52603053

Replay Dial-in Number: (855) 859-2056

Replay International Dial-in Number: (404) 537-3406

Conference ID: 52603053

## About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit [www.biomarin.com](http://www.biomarin.com).

### Contacts:

#### Investors

Traci McCarty

BioMarin Pharmaceutical Inc.

(415) 455-7558

#### Media

Debra Charlesworth

BioMarin Pharmaceutical Inc.

(415) 455-7451

---

<https://investors.biomarin.com/2016-07-21-BioMarin-to-Provide-Updated-Data-for-BMN-270-in-Hemophilia-A-in-Late-Breaking-Oral-Presentation-at-the-World-Federation-of-Hemophilia-WFH-2016-World-Congress-July-27th>